Waiv key facts
as of Oct 2026- Developer of artificial intelligence-based diagnostic tests designed to support precision oncology and biomarker-driven medicine.
- Waiv is valued at approximately $499.1M as of Oct 2026 (last reported valuation).
- It has raised $32.9M; the latest was Early Stage VC ($32.9M) in Mar 2026.
- Notable investors include Serena, OTB Ventures, Alpha Intelligence Capital, Karista (Paris), SISTAFUND.
- Status: Privately Held (backing).
Waiv's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·Watch Waiv: the Monday email on marks, rounds and moves
Waiv funding rounds
No funding rounds for Waiv are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Waiv valuation
Waiv's last reported valuation was $499 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
Waiv investors
5 investors are on record for Waiv, including Serena, OTB Ventures, Alpha Intelligence Capital and Karista (Paris).
About Waiv
Developer of artificial intelligence-based diagnostic tests designed to support precision oncology and biomarker-driven medicine. The company applies machine learning and foundation models to histopathology and multimodal clinical data, offering AI-enabled biomarker discovery, risk and outcome prediction, treatment-response assessment, and workflow integration with pathology and oncology systems, enabling healthcare providers and biopharmaceutical companies to conduct scalable, data-driven testing that supports targeted therapies, clinical decision-making, and streamlined diagnostic pathways across oncology.
- Sector
- Healthcare
- HQ
- Paris, France
- Website
- wearewaiv.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.